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Introduction
Locally advanced non-small cell lung cancer (NSCLC) is 
defined as a lung tumor that has spread to nearby tissue 
or lymph nodes (National Cancer Institute definition). 
According to the 8th edition of the TNM lung cancer 
staging manual, locally advanced NSCLC comprises a wide 
range of clinical presentations including primary tumor 
extension into extrapulmonary structures (T3 or T4) or 
mediastinal lymph node involvement (N2 or N3), without 
presence of distant metastases (M0). Patients with extensive 
mediastinal N2 infiltration are considered unresectable and 
are candidates for non-surgical multimodality strategies. 
The standard of care for fit patients is concomitant 
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chemoradiotherapy (CTRT) followed by durvalumab. 
Concomitant CTRT demonstrated superiority to sequential 
treatment in patients with stage III disease in terms of 
overall survival (OS) and reduced risk of locoregional 
progression (1). However, only 20–25% of patients with 
stage III NSCLC treated with concurrent CTRT will 
become long-term survivors (1,2).
Several studies have attempted to improve outcomes 
in this clinical setting exploring novel systemic therapies 
such as cytotoxic compounds (pemetrexed), biological 
drugs (cetuximab or gefitinib), vaccines targeting specific 
glycoproteins (tecemotide) or escalating the dose of 
radiotherapy (3-6). After many negative clinical trials in this 
setting, in the PACIFIC trial consolidation therapy with 
durvalumab after concurrent CTRT improved disease-
free survival (DFS) and OS compared with placebo; thus, 
becoming the current standard of care in patients with 
locally advanced, unresectable, stage III NSCLC (7).
Clinical trials evaluating concurrent CTRT show that 
about one-third of the patients (35–43%) will develop 
locoregional failure (8-10). Therefore, incorporating 
surgical resection to the treatment regimen of patients 
with stage III NSCLC may reduce the locoregional failure 
and improve the cure rate. Furthermore, surgical resection 
allows to examine treatment pathological response and 
tumor downstaging more accurately compared with 
radiological assessment. Induction therapy allows to start 
systemic treatment earlier and may increase compliance 
and tolerability of systemic therapy compared with adjuvant 
treatment. In this regard, the NSCLC Meta-analysis 
Collaborative Group demonstrated that preoperative 
chemotherapy achieved comparable survival benefit to adjuvant 
chemotherapy in patients with stage II–III disease (11).
However, within this heterogeneous group of patients 
with locally advanced NSCLC, only a minority of patients 
with central tumors or enlarged, discrete hilar or mediastinal 
lymph nodes are potentially resectable. These patients 
should be considered for invasive mediastinal staging, 
evaluated by an experienced multidisciplinary team, and 
should receive multimodal treatment as standard of care.
In this review, we aim to analyze the lessons learned from 
clinical trials evaluating induction chemotherapy with or 
without radiotherapy followed by surgery in patients with 
stage III NSCLC and apply them to the growing evidence 
supporting the use of immunotherapy in the neoadjuvant 
setting.
Role of surgery in stage IIIA–N2 NSCLC
Four randomized controlled trials (RCTs) addressed the 
role of surgery in stage III NSCLC (Figure 1, Table 1). 
Two studies compared induction chemotherapy followed 
by surgery (with or without postoperative radiotherapy) 
versus definitive sequential CTRT [NTOG (12), EORTC- 
08941 (13)] and two compared concomitant CTRT with or 
without surgery [INT0139 (14), ESPATUE (15)].
NTOG trial (12)
This phase III clinical trial randomized patients with IIIA–
Figure 1 Design of most relevant clinical trials on induction therapy in stage III NSCLC. NSCLC, non-small cell lung cancer; CT, 
chemotherapy; cCTRT, concurrent chemoradiotherapy; RT, radiotherapy; sCTRT, sequential chemoradiotherapy; S, surgery.
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N2 NSCLC to induction with paclitaxel 225 mg/m2 plus 
carboplatin AUC6 every 3 weeks for 3 courses, followed by 
surgery and then postoperative radiotherapy (arm A) versus 
definitive sequential CTRT (arm B). To detect an absolute 
increase of 10% in 5-year OS, 406 patients were estimated 
to be required. However, the study closed after recruiting 
341 patients, since concomitant CTRT became standard of 
care instead of sequential treatment. Surgery was performed 
in 132 of 170 patients (78%) and 121 (71%) had a complete 
resection. Pathologic complete response (pCR) was achieved 
in 4% of patients. Median progression-free survival (PFS), 
OS and 5-year survival rate were numerically longer in arm 
A (10 months, 17 months, and 20%, respectively) compared 
with arm B (8 months, 15 months, and 16%, respectively); 
however, these differences were not statistically significant. 
Despite carrying out this trial over 11 years in more than 300 
patients, it was not sufficiently powered to detect a clinically 
relevant advantage of surgery after sequential CTRT.
EORTC-08941 trial (13)
This study addressed the same question as the NTOG trial 
but focused on stage IIIA–N2 patients deemed unresectable 
at baseline. The primary endpoint was OS and 640 patients 
were estimated to be needed to detect an absolute increase 
of 10% in 5-year OS, with 80% power and type 1-error 
of 5%. Cisplatin-based induction chemotherapy was 
administered to 579 patients recruited over 8 years. Only 
332 responding patients (57%) were randomized to either 
surgery (with a 47% rate of pneumonectomy) or sequential 
radiotherapy (60 Gy in 30 fractions). In the surgery arm, 
only half of the 332 patients achieved complete resection, 
with persisting ypN2 disease in 57% of the patients. The 
rate of pCR was low (5%) and there was no significant 
difference in OS (5-year OS was approximately 15% in 
both groups). A high mortality rate (7%) was observed 
after pneumonectomy, leading to an extremely low long-
term OS compared with other lung resections (5% vs. 27% 
of patients attaining 5-year OS, respectively). Overall, no 
survival benefit was observed from undergoing surgery 
after induction chemotherapy in patients with stage IIIA–
N2 disease that was unresectable at baseline and who were 
staged without using a PET scan.
INT 0139 trial (14)
This North American Intergroup clinical trial assessed the 
role of surgery following induction with CTRT. Patients 
with resectable stage IIIA–pN2 NSCLC received two cycles 
of cisplatin-etoposide concurrently with radiotherapy at a 
dose of 45 Gy in 25 fractions and were randomized to either 
surgery or completion of full dose radiotherapy (61 Gy). OS 
was the primary endpoint and, assuming a 25% 2-year OS 
rate for the control arm, 484 patients were needed to detect 
a 10% absolute improvement in the surgical arm. The trial 
was closed prematurely after 7 years due to slow accrual 
and futility, with 82% of the sample size recruited. No 
significant differences in survival were observed between 
both arms (the 5-year OS in the surgery arm was 27% vs. 
20% in the non-surgery group; P=0.10). A strikingly high 
mortality after pneumonectomy (25%) was observed, with 
14 of 16 treatment-related deaths occurring in the surgical 
group compared with only 3 (2%) in the non-surgical 
group. In an adhoc exploratory analysis, there was an 
improvement in OS for patients who underwent lobectomy 
compared with a matched cohort of patients treated 
with chemoradiation, but not for those who underwent 
pneumonectomy.
ESPATUE trial (15)
This trial addressed the use of an intensive regimen in a 
population with a more advanced disease. Patients with 
stage IIIA–pN2 or highly selected, potentially resectable 
stage IIIB disease received induction chemotherapy (3 cycles 
of cisplatin plus paclitaxel) followed by hyperfractionated 
radiotherapy (45 Gy) given concurrently with cisplatin plus 
vinorelbine. Only responding patients deemed resectable 
by a tumor board were randomized to either surgery or 
definitive radiotherapy boost with 20–25 Gy (up to a total 
dose of 65–71 Gy). Three hundred patients were estimated 
to be needed to demonstrate an increase in 5-year OS 
from 25% to 40% with surgery. The trial started in 2004 
and used contemporary staging methods such as brain 
imaging and 18F-FDG PET-CT and was closed in 2012, 
after an interim futility analysis when 246 patients had 
enrolled and 161 patients had been randomized (56% of 
planned accrual). Among 81 patients allocated to surgery, 
70 underwent surgery (25% had a pneumonectomy) and 
66 achieved a complete resection, with a pCR rate of 
33% (27/81). Mediastinal downstaging was not reported. 
Intriguingly, none of the treatment-related deaths in the 
surgery arm (5/70) were after pneumonectomy, in contrast 
with what was observed in other trials in this setting. The 
trial was negative at the futility analysis because the control 
arm performed as well as the experimental arm, with 
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an impressive 5-year OS of 40% and 44%, respectively; 
the highest reported in this setting. Stage migration and 
selection bias after an intensive induction regimen might 
partially explain these outcomes.
Over two decades, more than 1,200 patients were 
treated in randomized trials; however, it was not possible 
to demonstrate a significant benefit in OS with surgery 
after induction chemotherapy or CTRT compared with 
definitive sequential or concomitant CTRT. Nevertheless, 
these trials were not powered to detect small but clinically 
relevant differences in OS. Moreover, achieving a complete 
resection, mediastinal downstaging, and pCR have emerged 
as prognostic factors of longer OS following induction 
treatment.
Induction with chemotherapy versus CTRT 
before surgery in stage IIIA–N2 NSCLC
Despite the discouraging results of trials comparing 
surgery versus thoracic radiotherapy after induction with 
chemotherapy or CTRT, additional clinical trials were 
designed to evaluate the role of chemotherapy alone versus 
CTRT before surgical resection in patients with locally 
advanced NSCLC (Figure 1, Table 1).
SAKK00/16 trial (16)
This is the only study comparing induction chemotherapy 
with or without sequential radiotherapy. Patients with stage 
IIIA–pN2 disease were randomized to induction treatment 
either with chemotherapy alone (cisplatin plus docetaxel) or 
with sequential CTRT (44 Gy in 22 fractions in 3 weeks), 
followed by surgery. To detect an improvement in event-free 
survival (EFS) of 6 months it was estimated that 240 patients 
would be required. After 11 years, the trial closed due to slow 
accrual, having almost completed the planned recruitment 
(232 patients). Although the rates of response (61% vs. 
44%), complete resection (91% vs. 81%), mediastinal 
downstaging (64% vs. 53%) and pCR (16% vs. 12%) were 
higher in patients treated with induction CTRT, there were 
no statistically significant differences either in EFS (12.8 vs. 
10.5 months) or in OS (37.1 vs. 26.2 months). A limitation 
of this study was that thoracic radiotherapy was given 
sequentially instead of concurrently with chemotherapy.
GLCCG trial (17)
This  s tudy  was  sponsored by  the  German Lung 
Cancer Cooperative Group (GLCCG) and assessed 
whether preoperative CTRT was superior to induction 
chemotherapy prior to surgery in patients with locally 
advanced NSCLC. Eligible patients had stage IIIA–N2 
(30%) or stage IIIB (70%) that was deemed potentially 
resectable; although, they would’ve been considered 
unresectable in clinical practice. Patients were randomized 
to receive an induction regimen of 3 cycles of cisplatin plus 
etoposide alone or followed by twice daily radiation with 
concurrent carboplatin and vindesine. The primary endpoint 
was PFS and 500 patients were estimated to detect a 
3-month increase in OS from a median of 10 months in the 
control group. It took 8 years to complete the recruitment of 
524 patients with stage III disease. Across both arms, there 
was a similar proportion of patients who underwent surgery. 
However, 44% of the patients did not undergo resection, 
given the high proportion of patients with stage IIIB that 
was enrolled. The rate of pneumonectomy was similar in 
both arms (35%). As in the SAKK trial, addition of CTRT 
to induction showed higher rates of complete resection 
(55% vs. 69%), mediastinal downstaging (29% vs. 46%), 
and major pathologic response (MPR, 20% vs. 60%), which 
did not translate into a significant improvement in PFS or 
OS (median OS 17.6 vs. 15.7 months). Treatment-related 
deaths were higher in the interventional group compared 
with the control group, particularly after pneumonectomy 
(14% vs. 6%) but also after lobectomy (7.5% vs. 2%).
Additional randomized clinical trials comparing different 
induction regimens were conducted in this clinical setting 
but closed early due to slow accrual.
WJTOG9903 trial (18)
This study was sponsored by West Japan Thoracic 
Oncology Group (WJTOG) and compared chemotherapy 
(carboplatin plus docetaxel) alone with chemotherapy plus 
40 Gy of concurrent thoracic radiotherapy in patients with 
stage IIIA–N2. The trial was closed early after recruitment 
of only 60 of the 180 required patients. The addition of 
radiotherapy to induction chemotherapy conferred better 
local control but differences observed in OS were not 
significant due to lack of statistical power. Mediastinal 
downstaging was associated with better outcome after 
surgery.
IFCT-0101 trial (19)
This multicenter randomized phase II clinical trial was 
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sponsored by the French Cooperative Thoracic Intergroup 
(IFCT). Patients with stage IIIA/pN2 tumors were 
randomized into 3 arms: chemotherapy alone with cisplatin 
plus gemcitabine or radiotherapy concurrent with either 
cisplatin plus vinorelbine or carboplatin plus paclitaxel. 
About 50 patients in each arm were needed to demonstrate 
the primary endpoint of feasibility, but the trial closed early 
due to very slow accrual after enrolling only 46 patients 
over 4 years. Amongst the 42 patients with resected tumors, 
35 patients had a complete resection, 16 patients showed 
mediastinal downstaging, and 2 (5%) patients achieved 
pCR. Feasibility was superior in the chemotherapy alone 
arm (93%) but the study was not powered to detect 
meaningful differences.
A systematic review and meta-analysis of 12 studies with 
2,724 patients demonstrated higher tumor downstaging 
(P=0.01), pCR (P=0.028), and local control (P=0.002) with 
preoperative CTRT compared with chemotherapy alone; 
however, it did not translate into a higher 5-year OS rate 
or a PFS benefit (20). Real world data has supported these 
findings. A study based on the SEER database showed that 
induction with CTRT led to a higher rate of mediastinal 
downstaging than chemotherapy alone in a cohort of 
T1–2N2 patients. However, induction with CTRT did not 
improve OS compared with chemotherapy alone (5-year 
OS of 41.4% vs. 40.8%, respectively) (21).
Based on the abovementioned results from clinical 
trials, clinical guidelines for locally advanced NSCLC 
with discrete N2 involvement identified preoperatively 
recommend either definitive CTRT or induction with 
chemotherapy or CTRT followed by surgery (22,23). 
Each treatment plan should be established within a 
multidisciplinary team with at least a thoracic surgeon, 
a medical oncologist, and a radiation oncologist. As 
preoperative chemotherapy is the preferred option rather 
than concurrent CTRT for resectable stage IIIA–N2 
NSCLC, induction chemotherapy has been considered the 
control arm or the backbone in recent randomized clinical 
trials testing neoadjuvant immunotherapy.
Clinical endpoints in trials evaluating 
neoadjuvant therapies
OS and DFS are considered gold-standard endpoints in 
phase III clinical trials with curative intent in early-stage 
NSCLC. However, these long-term endpoints can take 
years to mature. To accelerate and increase the efficiency 
of clinical trials, surrogate endpoints reflecting the study 
intervention are often used to predict clinical benefit.
pCR, defined as the eradication of all tumor from 
resected primary tumor and lymph nodes, has been used 
as a surrogate endpoint of OS and DFS in breast cancer 
neoadjuvant clinical trials. However, its rarity in NSCLC 
(4%, range, 0–16%) has restricted its use as a surrogate 
in this clinical setting. MPR, defined as ≤10% of residual 
viable tumor (RVT), has been proposed as an alternate 
surrogate since it correlates with OS and DFS in patients 
with resected NSCLC after neoadjuvant chemotherapy, 
even after adjusting for pathological stage. MPR occurs 
in about 20% of patients with NSCLC after neoadjuvant 
chemotherapy and may predict long-term OS, but 
prospective studies are still needed to confirm its validity 
and reproducibility in this setting (24). As these surrogate 
endpoints were developed in the context of neoadjuvant 
chemotherapy, its validity after novel therapies such as 
immunotherapy is unknown and should be investigated. 
Due to the histological changes seen in the regression bed 
(dense immune infiltration by lymphocytes, macrophages 
and tertiary lymphoid structures; massive tumor cell-
cholesterol clefts; tissue repair-neovascularization and 
proliferative fibrosis), an immune-related RVT (irRVT) has 
been proposed with improved interobserver consistency 
compared to classic RVT (25). This novel endpoint should 
be prospectively evaluated in trials assessing immunotherapy 
alone or in combination with other therapies to confirm its 
ability to predict DFS and OS.
Immune checkpoint inhibitors (ICIs) as 
neoadjuvant treatment in resectable stage III 
NSCLC
ICIs against the programmed death-1 (PD-1) and 
programmed death-ligand 1 (PD-L1) have transformed 
treatment for patients with locally advanced or metastatic 
NSCLC. Significant improvements in OS have established 
ICIs as standard of care in the first-line setting in advanced 
NSCLC and as consolidative treatment after concurrent 
CTRT in stage III NSCLC (26). The combination of 
ICI with chemotherapy also improved results in phase III 
clinical trials (27-33) and appears to successfully induce 
immunogenic cell-death and inhibit the immunosuppressive 
tumor microenvironment (34,35).
The immune cell composition changes as the tumor 
progresses: earlier stages are enriched for T-effector 
memory CD8+ cells, while advanced tumors are enriched 
for Tregs and myeloid-derived suppressive cells (36). 
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Preclinical and clinical studies have suggested that 
neoadjuvant ICI might be superior to adjuvant treatment 
because it can induce a stronger and more prolonged 
systemic and antitumor T-cell immune response (37-39). 
Intact primary tumor and drainage to the regional lymph 
nodes are thought to induce greater immune response 
compared with the micro-metastatic disease remaining 
after surgical resection of the tumor. Several studies have 
explored the activity of ICI alone or in combination with 
chemotherapy to improve the cure rate in patients with 
earlier stages of NSCLC.
Clinical trials evaluating ICI or ICI plus 
chemotherapy in the neoadjuvant setting
We have reviewed the studies that assessed the safety 
and efficacy of induction with anti-PD-1 or anti-PD-L1 
therapies given alone or in combination with anti-CTLA-4 
or platinum-based chemotherapy. All studies are listed in 
Table 2.
CheckMate 159 trial (40)
This single arm, phase Ib–II, clinical trial is the seminal 
study assessing neoadjuvant anti-PD-1 therapy in patients 
with resectable stage IB–IIIA NSCLC (40). Two doses of 
nivolumab were administered prior to surgery in 22 patients. 
The primary endpoints were safety and feasibility and the 
key secondary were radiologic and pathological responses. 
Neoadjuvant nivolumab showed an acceptable safety 
profile and there was only one grade ≥3 immune-related 
adverse event (irAE) (skin rash). Twenty of the 22 patients 
enrolled underwent resection (one patient was deemed 
unresectable and other had small cell carcinoma histology). 
Surgery was not delayed in any patient and there was no 
operative mortality (a single patient died of traumatic 
injury on postoperative day 61). Morbidity occurred in 10 
of 20 patients (50%). The most common postoperative 
complication was atrial arrhythmia (6/20; 30%). The other 
complications were a concomitant myocardial infarction, 
pneumonia and pulmonary embolism, prolonged air leak 
and urinary infection, and empyema (41). Of the 21 patients 
evaluable for radiographic response, 2 patients (10%) had 
a partial response (PR), 18 (86%) had stable disease (SD), 
and 1 (5%) had disease progression (PD). MPR evaluated in 
the tumor and lymph nodes was observed in 45% (95% CI: 
23–68%) (9/20) of resected tumors and 2 patients achieved 
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L1 expression but were correlated with the pretreatment 
tumor mutational burden (TMB). After a median follow up 
of 34.6 months, median recurrence-free survival (RFS) and 
OS had not been reached yet.
NEOSTAR trial (42)
This is a non-comparative phase II clinical trial testing 
nivolumab alone or in combination with ipilimumab prior 
to surgery in patients with stage I–IIIA resectable NSCLC. 
The study enrolled 44 patients who were randomized to 
neoadjuvant nivolumab (3 mg/kg on days 1, 15, 29) (n=23) or 
nivolumab plus ipilimumab (1 mg/kg on day 1) (n=21). The 
primary endpoint was MPR. Across both arms, 39 patients 
underwent post-ICI surgery; however, 2 patients were 
resected off trial because they received chemotherapy in 
addition to ICI (1 patient with suspected PD and 1 patient 
with grade 3 immune-related diarrhea). Five patients did 
not undergo surgery due to: 2 patients with PD, 1 patient 
with grade 3 hypoxia from pleural effusion, 1 patient had 
high surgical risk, and 1 patient declined surgery (42). The 
overall response rate (ORR) by RECIST v1.1 was 20% [8 
PR (5 nivolumab, 3 combination) and 1 CR (combination)] 
and 14% of patients had PD (3 nivolumab, 3 combination). 
Among the intention-to-treat (ITT) population (n=44), 
11 patients achieved MPR (25%), 4 in the nivolumab arm 
and 7 in the combination arm. Eight patients achieved pCR 
(15%), 2 in the nivolumab arm and 6 in the combination 
arm. Among the 37 patients with on-study resection, the 
MPR rate was 30% (4 receiving nivolumab, 7 receiving the 
combination). Objective response by RECIST was higher 
in patients who achieved MPR than in those that did not [7 
(78%) vs. 2 (22%); P<0.001]. A novel phenomenon, called 
nodal immune flare (NIF), was observed in some patients 
who experienced apparent radiographic nodal progression, 
but the pathologic examination revealed only granulomas 
without the presence of tumor cells. There were 8 patients 
(22%) in whom surgery was delayed beyond 42 days 
(3 patients in the nivolumab arm and 5 in the combination 
arm). Surgical complications included 2 bronchopleural 
fistulas in the nivolumab arm and 8 prolonged air leaks 
(5 in patients receiving nivolumab, 3 receiving the 
combination). Grade ≥3 treatment-related adverse events 
(TRAEs) included a death due to bronchopleural fistula 
following an immune-related pneumonitis treated with 
corticosteroids (grade 5 in a patient receiving nivolumab); 
grade 3 pneumonia, hypoxia, hypermagnesemia (1 each, all 
receiving nivolumab) and grade 3 diarrhea, hyponatremia 
(1 each, all receiving the combination). Baseline tumor PD-
L1 expression was associated with radiological (P=0.015) 
and pathological responses (P=0.015) (43).
LCMC3 trial (44)
In this single arm phase II clinical trial, patients with 
resectable stage IB–IIIB NSCLC received neoadjuvant 
atezolizumab (1,200 mg for 2 cycles) followed by surgery 
and then standard of care chemotherapy followed by 
atezolizumab for 1 year. The interim analysis was based on 
the first 101 of 180 planned patients. Stage IIIA and IIIB 
accounted for 39% and 7% of the patients, respectively. 
The primary endpoint was the MPR rate. Of 101 patients, 
11 patients were not resected due to: 5 patients with PD, 
4 patients withdrew informed consent, 1 patient had 
echocardiogram alterations, and 1 patient was deemed 
unresectable. The primary efficacy population (n=77) 
excluded 6 patients without MPR assessment and 7 patients 
who harbored driver mutations. The MPR rate in the 
primary population was 19% (15/77, 95% CI: 11–30) and 
4 patients (5%) had pCR. In per protocol (PP) population 
(n=90), 6 patients (7%) had PR, 80 (89%) had SD and 4 (4%) 
had PD by RECIST v1.1. The 12-month DFS calculated 
from the date of surgery was 89% (95% CI: not reported). 
Pre-operative irAEs were reported in 30 patients (30%). 
The majority of them were grade 1 or 2 (12 skin rash, 10 
infusion-related reaction, 4 abnormal thyroid function and 
5 elevated liver enzymes) and only 1 grade 3 was reported 
(pneumonitis). In this study, pathological regression and 
MPR did not correlate with PD-L1 expression or with 
TMB evaluated by whole exome sequencing.
ChiCTR-OIC-17013726 trial (45)
This single arm phase II trial assessed the efficacy and safety 
of sintilimab, an anti-PD-1 antibody, in the neoadjuvant 
setting in patients with resectable stage IB–IIIA NSCLC. 
Primary endpoints were drug safety, surgical complications, 
and no-delay of surgery rate. Secondary endpoints were 
ORR, MPR, DFS at 1 and 2 years and OS at 2 years. Forty 
patients received 2 cycles of sintilimab (200 mg IV on days 1 
and 22) of whom 37 underwent surgery. Two patients had 
a treatment-related operation delay. Most patients received 
adjuvant sintilimab alone (40.5%), but some patients 
received adjuvant chemotherapy plus sintilimab (27%) or 
conventional adjuvant chemotherapy (11%). The ORR was 
20% and 15 patients achieved MPR (40.5%, 95% CI: 24.8–
547Translational Lung Cancer Research, Vol 10, No 1 January 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(1):539-554 | http://dx.doi.org/10.21037/tlcr-20-420
57.9%), including 6 who had pCR (16.2%, 95% CI: 6.2–
32.0%). Twenty-one patients (52.5%) had TRAEs during 
the neoadjuvant phase, but only 4 patients (10%) reported 
grade 3–4 TRAEs and one patient had a grade 5 TRAE.
NADIM trial (46)
This single arm phase II clinical trial was the first 
multicenter study testing chemo-immunotherapy in 
the neoadjuvant setting in patients with resectable stage 
IIIA NSCLC. This academic study was sponsored by 
the Spanish Lung Cancer Group (GECP). Neoadjuvant 
treatment consisted of three cycles of nivolumab 360 mg 
+ paclitaxel 200 mg/m2 + carboplatin AUC 6 IV Q3W 
prior to surgery. Adjuvant treatment with nivolumab was 
given for 1 year (nivolumab 240 mg IV Q2W for 4 months 
and then nivolumab 480 mg IV Q4W for 8 months). The 
primary endpoint was PFS at 24 months from the first dose 
of neoadjuvant treatment. Forty-six patients were included 
and received neoadjuvant treatment. In the ITT population 
(n=46), 34 patients (74%, 95% CI: 60–85%) achieved 
MPR and 24 patients had pCR (52%, 95% CI: 38–66%). 
Based on RECIST v1.1, the ORR was 74% (69.6% and 
4.3% achieved PR and CR, respectively). The neoadjuvant 
treatment was generally well tolerated, and there were 
no surgery delays. All surgical resections were R0 and no 
intraoperative complications were seen. Only 12 patients 
(29%) presented postsurgical complications; the most 
frequent were: 5 patients with respiratory infections, 
4 patients with episodes of cardiac arrhythmias, and 
2 patients with prolonged air leak. There was no surgery-
related postoperative mortality. After a median follow-up of 
17.1 months, PD was reported in 6 patients (1 patient with a 
CR but found to harbor an EGFR mutation, 3 patients with 
>10% of RVT, and 2 patients with no surgery). In the PP 
population (n=41), the MPR was 83% (95% CI: 68–93%) 
and pCR 59% (95% CI: 42–74%). Seven patients (17%) 
patients presented >10% of RVT. Within the overall ITT 
population, the PFS at 12 and 18 months was 96% (95% 
CI: 84–99%) and 81% (95% CI: 61–91%), respectively. 
The OS rate at 12 and 18 months was 98% (95% CI: 85–
100%) and 91% (95% CI: 73–97%). In the PP population, 
the PFS rate at 12 and 18 months was 100% and 87% 
(95% CI: 64–96%), respectively and the OS rate at 12 and 
18 months was 100% and 95% (95% CI: 68–99%). In terms 
of safety, 24.2% of the patients reported grade ≥3 TRAEs. 
The majority of these TRAEs were chemotherapy-related 
and only one patient reported a grade 3 TRAE (nephritis).
NCT02716038 trial (47)
A single-arm phase II clinical trial evaluated the combination 
of atezolizumab with carboplatin plus nab-paclitaxel in 
patients with resectable stage IB–IIIA NSCLC. The 
number of induction cycles administered in this study was 
based on the radiological response after the first two cycles. 
Patients with a response could receive two additional cycles, 
while patients in whom tumor progression was observed 
went directly to surgery. The primary endpoints were 
MPR and time to surgery. Fourteen evaluable patients 
(85% stage IIIA) were enrolled. Eleven patients underwent 
resection successfully and 7/14 (50%) patients achieved 
MPR, including 3 patients (21%) with pCR. Pathological 
responses were observed regardless of PD-L1 expression. 
Eight patients (57%) had radiologic PR and the remainder 
had SD. With a median follow-up of 8.6 months, PD was 
reported in 4 patients (2 chest recurrences and 2 brain 
metastases). The most common toxicity was neutropenia 
(71% grade 3–4), with 64% patients requiring a dose 
reduction of chemotherapy.
SAKK16/14 (48)
A single-arm phase II clinical trial evaluated three cycles 
of cisplatin plus docetaxel followed by two cycles of 
durvalumab in patients with resectable stage IIIA NSCLC. 
The primary endpoint was EFS. Sixty-seven evaluable 
patients were enrolled, but only 55 patients underwent 
resection. Thirty-three patients achieved MPR, including 
10 patients with pCR. Thirty-six out of 62 (58%) patients 
had radiologic response. With a median follow-up of 
28 months, 14 patients had progressed and median EFS has 
not been reached. The EFS at 1 year was 73.3% (95% CI: 
62.5–81.4). There were two fatal adverse events (AEs): one 
respiratory failure during the induction chemotherapy and 
one bronchopulmonary hemorrhage after surgery.
There are several ongoing phase II/III clinical trials 
assessing ICI in combination with chemotherapy in the 
neoadjuvant setting (Table 3).
NADIM II (NCT03838159) is an open-label randomized 
phase II clinical trial sponsored by the Spanish Lung Cancer 
Group. Ninety patients will be enrolled to determine the 
pCR in patients treated with the NADIM neoadjuvant 
chemo-immunotherapy schema followed by a shorter 
adjuvant treatment with nivolumab for 6 months versus 
carboplatin plus paclitaxel for three cycles followed by 
surgery.
548 Palmero et al. Neoadjuvant strategies in resectable locally advanced NSCLC
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(1):539-554 | http://dx.doi.org/10.21037/tlcr-20-420
CheckMate 816 (NCT02998528) is an international, 
open-label, randomized phase III clinical trial in patients 
with stage IB–IIIA NSCLC comparing neoadjuvant 
t rea tment  w i th  n ivo lumab  p lus  p l a t inum-based 
chemotherapy versus platinum-based chemotherapy alone. 
This study originally had a third arm with ipilimumab plus 
nivolumab that was stopped. Co-primary endpoints are EFS 
and pCR rate.
KEYNOTE-671 (NCT03425643) is an international, 
double-blinded, randomized phase III clinical trial investigating 
the  combinat ion of  neoadjuvant  p lat inum-based 
chemotherapy plus placebo prior to surgery and adjuvant 
placebo for 1 year versus neoadjuvant platinum-based 
chemotherapy plus pembrolizumab prior to surgery and 
adjuvant pembrolizumab in patients with resectable stage 
IIB or IIIA NSCLC. Primary endpoints are EFS and OS.
IMpower030 (NCT03456063) is a multicenter, double-
blinded, randomized phase III clinical trial assessing 
atezolizumab efficacy in combination with platinum-
based chemotherapy in patients with resectable (II, IIIA 
or selected IIIB) NSCLC. Patients received four cycles of 
atezolizumab versus placebo combined with platinum-based 
chemotherapy. After surgery only those patients randomized 
to atezolizumab will continue ICI treatment until a 
maximum number of 16 cycles. Co-primary endpoints are 
MPR and EFS.
Durvalumab is also currently being investigated in several 
phase II neoadjuvant studies, including the IONESCO 
study (NCT03030131), NCT02572843 (durvalumab plus 
cisplatin + docetaxel) and NCT02904954 (durvalumab plus 
stereotactic body radiation therapy) and in the phase III 
clinical trial AEGEAN (NCT03800134) in combination 
with platinum-based chemotherapy.
Biomarkers of response to ICI neoadjuvant 
therapy
Neoadjuvant trials are an ideal setting for exploring 
predictive biomarkers. PD-L1 expression and TMB, 
biomarkers for immunotherapy in advanced NSCLC, 
have not shown a consistent association with response to 
neoadjuvant immunotherapy. Tumor responses occurred 
in both PD-L1 positive and PD-L1 negative tumors and 
whereas a positive correlation between the pathological 
response and the baseline TMB was reported in the 
LCMC3 trial (40), no correlation was found between both 
parameters.
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(CheckMate 159), T-cell receptor (TCR) repertoire was 
significantly expanded in patients who achieved MPR after 
the second dose of nivolumab (49). In addition, clearance of 
plasma circulating tumor DNA (ctDNA) prior to surgery 
was detected in all patients who achieved ≥30% reduction 
in RVT and had pre-treatment detectable ctDNA. 
Furthermore, higher intratumoral TCR clonality was 
correlated with reduced residual tumor at the time of the 
surgery; peripheral expansion of tumor-specific T-cells and 
long-term persistence were associated with longer DFS (50).
In the NEOSTAR trial, the TCR repertoire was 
measured in pre-treatment biopsies, surgical specimens, 
matched adjacent normal lung, as well as paired blood at 
baseline, prior to surgery, and 8 weeks post-surgery (n=44). 
Neoadjuvant therapy benefit was associated with higher 
clonality in tumors and lower clonality in blood post-
therapy, suggesting increased T cell trafficking into the 
tumor (differences not statistically significant). Moreover, 
higher pretreatment TCR clonality in the blood was 
associated with a lower percentage of RVT at time of 
surgery in both treatment arms (P=0.04) (51).
In  the  a tezo l i zumab wi th  chemotherapy  t r i a l 
(NCT02716038), blood immune phenotyping by flow 
cytometry (n=61) showed that T- and NK-cells levels were 
lower at baseline in patients who achieved MPR than in 
those who did not achieve MPR. Among 48 patients with 
paired pre- and post-treatment peripheral blood samples, 
the expansion of NK-cells and granulocytes and the 
contraction of monocytes were significantly correlated with 
achieving a MPR. Furthermore, a lymph node immune-
phenotyping analysis performed in 28 patients showed 
a significant increase in memory T-cells (CD3+ CD27+ 
CD45RO+) and a decrease in regulatory T-cells (CD3+ 
CD4+ CD25+) in the MPR population. The association 
between immune cells and irAEs was explored in 55 
patients, showing that granulocytes and dendritic subsets 
were higher in patients who developed irAEs (44).
In the NADIM trial, blood samples were obtained pre- 
and post-neoadjuvant treatment. Absolute number of cells 
in the hemogram (n=41) and peripheral blood mononuclear 
immune cells (PBMCs) (n=27) were analyzed as potential 
biomarkers of response to immunotherapy. A higher 
decrease on the platelets-to-lymphocytes ratio (PLR) post 
treatment was associated with incomplete pathological 
response (≥10% RVT). Higher levels of PD-1 expression 
in CD4 T cells at baseline was associated with pCR. A 
reduction of PD-1 detection in CD4 T cells, CD8 T cells 
and NK cells and a decrease in CD4 T cells and NK cells 
activation after neoadjuvant treatment was also associated to 
pCR (52).
Due to the limited number of samples analyzed across 
these studies, the differences in the techniques employed, 
and the short follow-up of these clinical trials, further 
clinical trials are needed to validate biomarkers predicting 
benefit from neoadjuvant ICI.
Discussion
Locally advanced NSCLC is a highly heterogeneous 
disease requiring a multidisciplinary team-based treatment 
approach. As more than a third of the patients (35–43%) 
will develop locoregional failure and only a quarter of the 
patients (20–25%) will achieve long-term survival with 
concurrent CTRT, surgery has been intensively studied 
in patients with discrete N2 involvement and resectable 
disease. However, most trials evaluating surgery in stage 
III NSCLC following induction treatment were not 
powered to detect small differences in survival outcomes. 
Induction chemotherapy with radiotherapy was associated 
with higher rates of tumor downstaging and pCR than 
chemotherapy alone (4–5% vs. 16–60%, respectively); 
however, these did not translate into better long-term 
outcomes, nor higher cure rates (5-year OS 41.4% vs. 
40.8%, respectively). Therefore, induction chemotherapy 
has been adopted as the control arm in clinical trials 
evaluating neoadjuvant immunotherapy. The percentage 
of RVT and MPR following neoadjuvant treatment has 
been evaluated or proposed as a surrogate marker for OS 
and DFS. As a limitation, those surrogate endpoints cannot 
capture TRAEs or whether lung resection has been feasible, 
which is highly relevant when novel agents are being 
tested for potentially curable disease. Furthermore, those 
endpoints should also be reinforced by long-term survival 
outcomes and be consistent with a higher cure rate. Several 
studies assessed the feasibility and efficacy of induction 
ICI alone or in combination with chemotherapy in early 
stage and resectable stage IIIA NSCLC. Neoadjuvant 
ICI monotherapy trials reported promising rates of MPR 
(17–45.5%) as well as pCR (9–29%), with relatively low 
toxicity and low progression rates without compromising 
resection rates (Figure 2). The addition of ICI to platinum-
based chemotherapy reported an unprecedented MPR 
rate of 50–83% and pCR of 21–59% (Figure 2). If these 
encouraging efficacy and safety results are confirmed in 
currently ongoing randomized clinical trials, induction 
based on chemotherapy plus ICI followed by surgery could 
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become standard of care for patients with resectable stage 
III NSCLC. Induction CTRT could still be considered 
standard of care in tumors invading chest wall or potentially 
resectable T4, but the high rate of pathological response 
achieved with neoadjuvant chemotherapy combined with 
ICI warrants further research also in these clinical scenarios.
Incorporating immunotherapy to the preoperative setting 
has several challenges including the assessment of radiologic 
and pathologic response, which indeed can be discordant. 
In this regard, pseudoprogression or the flare phenomenon 
have been observed and might mistakenly consider patients 
as inoperable. Standardized approaches to determine the 
degree of pathologic response are needed. Unfortunately, 
novel endpoints, such as immune-related percentage of 
RVT (%irRVT) are not prespecified endpoints in the 
ongoing clinical trials. Conversely, treatment strategies for 
those patients who will not achieve mediastinal downstaging 
or MPR have yet to be defined and the role of postoperative 
radiotherapy has not yet been established. Administering 
adjuvant treatment with ICI in the experimental arm is an 
additional limitation of ongoing clinical trials because it will 
not determine whether it is needed in all patients or only 
in those who do not achieve clinically relevant pathological 
response.
Identifying biomarkers for neoadjuvant ICI (alone or 
in combination with chemotherapy) is crucial to provide 
patients with the best therapeutic approaches and avoid 
induction therapy in patients at risk of progression and 
who may benefit from definitive concurrent CTRT. 
Although neoadjuvant trials provide an ideal platform for 
biomarker assessment, the association of PD-L1 and TMB 
with response to induction with immunotherapy has not 
been consistent in phase I/II clinical trials. This might be 
explained both due to differences in the study population or 
in the methods used, but also due to their limited statistical 
power for validating the predictive value of those markers.
The most appropriate treatment in patients with locally 
advanced NSCLC should be decided in the context of 
Figure 2 Rate of pathologic response, including pCR and MPR in clinical trials evaluating induction therapy in stage III NSCLC. *, ICI 
doublet. pCR, pathologic complete response; MPR, major pathologic response; NSCLC, non-small cell lung cancer; CT, chemotherapy; 
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experienced multidisciplinary tumor boards with the 
participation of thoracic surgeons with expertise not only in 
lung cancer surgery following neoadjuvant chemotherapy 
or CTRT, but also following induction with ICI. Although 
we anticipate a paradigm shift in the preoperative treatment 
of patients with stage III resectable NSCLC, we should wait 
for the results from randomized clinical trials evaluating 
induction with chemotherapy plus ICI before incorporating 
this treatment regimen into the clinical practice. We 
consider that allowing patients to participate in ongoing 
clinical trials is currently the most suitable strategy in 
this clinical setting. These clinical trials might validate 
pathological response as a surrogate marker of survival 
benefit in this clinical setting and will probably confirm 
whether this therapeutic strategy can improve the cure rate 
in patients with stage II–III NSCLC.
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